Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome

Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.

Read More
Spiro Katerinis
Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). 

Read More
Spiro Katerinis
Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the first patient has been enrolled at UNC-Chapel Hill Dermatology & Skin Cancer Center in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB).

Read More
Spiro Katerinis
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

Harmony Biosciences, LLC (Harmony), a Paragon Biosciences, LLC, portfolio company, today announced that it will present scientific data on its investigational product, pitolisant, which is being studied for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy, at the upcoming 32nd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP", in Baltimore, MD from June 3-6.

Read More
Spiro Katerinis
Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB).

Read More
Spiro Katerinis
Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America

Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the company received the Partners in Progress Award at the 19th Annual debra of America (Dystrophic Epidermolysis Bullosa Research Association of America) Benefit held October 26, 2017 at Guastavino’s in New York City.

Read More
Jennifer Murphy